Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 10

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 10
---
 3,342,188 of which were subsequently transferred to the Sponsor in connection with the Sponsor Alliance. Based on the closing price of the Public Shares of $         on the Record Date, the Initial Sponsor could earn a return of $         per share, or $         in the aggregate, upon the sale of its Founder Shares, corresponding to a rate of return of %. If the Closing occurs, such shares shall be converted into Company Shares and retained by APX Capital. If APx does not complete an initial business combination, such shares will expire worthless. See “Questions and Answers about the Business Combination and the Special Meeting — What equity stake will our current shareholders and shareholders of the Target hold in OmnigenicsAI immediately after consummation of the Business Combination?”, “Unaudited Pro Forma Combined Financial Information — Basis of Presentation,” and “Comparative Per Share Data.” |     |                                                                                                                                                                                                                                                                                                                                                                        |

The retention of Company Shares and Company Warrants by the Sponsor and the Initial Sponsor at Closing will not result in a material dilution of the equity interests of non -redeemingPublic Shareholders, other than in connection with the exercise of such Company Warrants. See “ Summary of the Proxy Statement / Prospectus — The Business Combination — Equity Ownership and Dilution following the Business Combination.” Conflicts of Interest In considering the recommendation of the APx Board to vote in favor of the Business Combination, shareholders should be aware that, aside from their interests as shareholders, our Sponsor and our directors and officers and the Company’s current shareholders have interests in the Business Combination that are different from, or in addition to, those of our other shareholders generally. Our directors were aware of and considered these interests, among

other matters, in evaluating the Business Combination, and in recommending to our shareholders that they approve the Business Combination. Shareholders should take these interests into account in deciding whether to approve the Business Combination. These interests include, among other things: •the Initial Shareholders will lose their entire investment in APx if APx does not complete an initial business combination by the Extended Date; •the beneficial ownership of the Initial Shareholders of an aggregate of 4,312,500 SPAC Class A Ordinary Shares, comprised of 3,342,188 SPAC Class A Ordinary Shares held by the Sponsor (which shares were purchased in connection with the Sponsor Alliance) and 970,312 SPAC Class A Ordinary Shares held by the Initial Sponsor (which were purchased in connection with APx’s initial public offering and which were retained in connection with